40 Facts About GSK plc

1.

GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England.

FactSnippet No. 969,088
2.

Legacy products developed at GSK plc include several listed in the World Health Organization's List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine and zidovudine.

FactSnippet No. 969,089
3.

GSK plc began to expand globally, buying seven laboratories in Canada and the United States in 1969.

FactSnippet No. 969,090
4.

GSK plc completed the acquisition of New Jersey-based Block Drug in 2001, for.

FactSnippet No. 969,091
5.

In 2006, GSK plc acquired the US-based consumer healthcare company CNS Inc, whose products included Breathe Right nasal strips and FiberChoice dietary supplements, for US$566million in cash.

FactSnippet No. 969,092
6.

In 2009, GSK plc acquired Stiefel Laboratories, then the world's largest independent dermatology drug company, for.

FactSnippet No. 969,093
7.

Also in November 2009, GSK plc formed a joint venture with Pfizer to create ViiV Healthcare, which specializes in HIV research.

FactSnippet No. 969,094
8.

In 2013, GSK plc acquired Human Genome Sciences for US$3billion; the companies had collaborated on developing the lupus drug Belimumab, albiglutide for type 2 diabetes, and darapladib for atherosclerosis, and in September, sold its beverage division to Suntory.

FactSnippet No. 969,095
9.

In March 2014, GSK plc paid US$1billion to raise its stake in its Indian pharmaceutical unit, GlaxoSmithKline Pharmaceuticals, to 75 percent as part of a move to focus on emerging markets.

FactSnippet No. 969,096
10.

In February 2015, GSK plc announced that it would acquire GlycoVaxyn, a Swiss pharmaceutical company, for US$190million, and in June that year that it would sell two meningitis drugs to Pfizer, Nimenrix and Mencevax for around US$130million.

FactSnippet No. 969,097
11.

On 3 December 2018, GSK plc announced that Unilever would acquire the Indian-listed GlaxoSmithKline Consumer Healthcare business for US$3.

FactSnippet No. 969,098
12.

In October 2019, GSK plc agreed to sell its rabies vaccine, RabAvert, and its tick-borne encephalitis vaccine, Encepur, to Bavarian Nordic for US$1.

FactSnippet No. 969,099
13.

In March 2018, GSK plc announced that it has reached an agreement with Novartis to acquire Novartis's 36.

FactSnippet No. 969,100
14.

In December 2018, GSK plc announced that it, along with Pfizer, had reached an agreement to merge and combine their consumer healthcare divisions into a single entity.

FactSnippet No. 969,101
15.

The deal builds on an earlier 2018 deal where GSK plc bought out Novartis' stake in the GSK plc-Novartis consumer healthcare joint business.

FactSnippet No. 969,102
16.

Culmination of the Consumer Healthcare string of deals will result in GSK plc splitting into two separate companies, via a demerger and subsequent listing of the joint venture.

FactSnippet No. 969,103
17.

On 22 February 2022, GSK plc announced that the spin-off consumer healthcare company will be called Haleon.

FactSnippet No. 969,104
18.

In May 2022, GSK plc announced it would acquire Affinivax and its phase II 24-valent pneumococcal vaccine candidate for up to $3.

FactSnippet No. 969,105
19.

In 2014, GSK plc applied for regulatory approval for the first malaria vaccine.

FactSnippet No. 969,106
20.

GSK plc has committed to making the vaccine available in developing countries for five percent above the cost of production.

FactSnippet No. 969,107
21.

GSK plc previously owned the Lucozade and Ribena brands of soft drinks, but they were sold in 2013, to Suntory for £1.

FactSnippet No. 969,108
22.

In September 2019, GSK plc announced it would acquire Sitari Pharmaceuticals and its transglutaminase 2 small molecule program for the treatment of celiac disease.

FactSnippet No. 969,109
23.

GSK plc has been active, with the World Health Organization, in the Global Alliance to Eliminate Lymphatic Filariasis .

FactSnippet No. 969,110
24.

Medecins Sans Frontieres welcomed the decision, but criticized GSK plc for failing to include HIV patents in its patent pool and for not including middle-income countries in the initiative.

FactSnippet No. 969,111
25.

In 2013, GSK plc licensed its HIV portfolio to the Medicines Patent Pool for use in children, and agreed to negotiate a license for dolutegravir, an integrase inhibitor then in clinical development.

FactSnippet No. 969,112
26.

Also in 2013 GSK plc joined AllTrials, a British campaign to ensure that all clinical trials are registered and the results reported.

FactSnippet No. 969,113
27.

GSK plc said it would make its past clinical-trial reports available and future ones within a year of the studies' end.

FactSnippet No. 969,114
28.

In 2001, the British Advertising Standards Authority required GSK plc to withdraw its claim that Ribena Toothkind, a lower-sugar variety, did not encourage tooth decay.

FactSnippet No. 969,115
29.

In 2010, the US Department of Justice announced that GSK plc would pay a US$150million criminal fine and forfeiture, and a civil settlement of US$600million under the False Claims Act.

FactSnippet No. 969,116
30.

In July 2012, GSK plc pleaded guilty in the United States to criminal charges, and agreed to pay US$3billion, in what was the largest settlement until then between the Justice Department and a drug company.

FactSnippet No. 969,117
31.

GSK plc set up a ghostwriting programme called CASPPER, initially to produce articles about Paxil but which was extended to cover Avandia.

FactSnippet No. 969,118
32.

The Justice Department said GSK plc had promoted rosiglitazone to physicians with misleading information, including that it conferred cardiovascular benefits despite an FDA-mandated label warning of cardiovascular risks.

FactSnippet No. 969,119
33.

GSK plc threatened to sue him, called his university head of department, and persuaded him to sign a retraction.

FactSnippet No. 969,120
34.

GSK plc raised questions internally about the drug's safety in 2000, and in 2002, the company ghostwrote an article in Circulation describing a GSK plc funded clinical trial that suggested rosiglitazone might have a beneficial effect on cardiovascular risk.

FactSnippet No. 969,121
35.

GSK plc had reportedly tried to persuade one of the authors, Steven Nissen, not to publish it, after receiving an advance copy from one of the journal's peer reviewers, a GSK plc consultant.

FactSnippet No. 969,122
36.

GSK plc conducted nine clinical trials between 1994, and 2002, none of which showed that Paxil helped children with depression.

FactSnippet No. 969,123
37.

GSK plc paid doctors to promote these off-label uses, and set up supposedly independent advisory boards and Continuing Medical Education programmes.

FactSnippet No. 969,124
38.

In 2006, in the United States GSK plc settled the largest tax dispute in IRS history, agreeing to pay US$3.

FactSnippet No. 969,125
39.

In October 2020, GSK plc told some staff that while at work they should disable the contact tracing function of the NHS test-and-trace app which monitors the spread of COVID-19.

FactSnippet No. 969,126
40.

GSK plc explained the reason for this was due to social distancing measures in place at their sites rendering the technology unnecessary.

FactSnippet No. 969,127